All Updates

All Updates

icon
Filter
Listing
Clario confidentially files for US IPO
Clinical Trial Technology
Jun 26, 2024
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
Clinical Trial Technology

Clinical Trial Technology

Jun 26, 2024

Clario confidentially files for US IPO

Listing

  • According to a Bloomberg report, Clario, a clinical trial technology solution provider, has confidentially filed for an initial public offering with the US Securities and Exchange Commission and is targeting a valuation of more than USD 10 billion. The report states that the company is working with underwriters JPMorgan Chase, Morgan Stanley, Jefferies Financial, and UBS Group AG.

  • While no final decisions have been made and deliberations are underway, one source in the report suggested that the company might consider a listing in 2025.  

  • Analyst QuickTake: As of June 2024, Clario has provided solutions for use in 26,000+ clinical trials across 100 countries, and has contributed to 800+ drug approvals. According to Bloomberg sources, the company is estimated to generate an annual revenue of USD 1.1 billion and an EBITDA of ~USD 400 million. While the company’s performance metrics could help support its aggressive initial valuation, a public filing with the SEC will need to be submitted to proceed with the listing.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.